Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers
- 21 Downloads
Circulating miRNAs are increasingly suggested as clinical biomarker for diseases. We evaluated the expression of circulating cardiomyocyte-enriched miR-1 and miR-133 by real-time PCR in blood from patients with type 2 diabetes (T2D) without and with coronary artery disease (CAD) and healthy controls, investigated their association with the risk of CAD risk and their potential as biomarkers. The two miRNAs were upregulated in patients with T2D and CAD compared with controls, associated with CAD risk and remained significant after adjustment for multiple confounders. LDL-C was a positive predictor for miR-1 and miR-133, and mean blood pressure was also a positive predictor for miR-133. Both miRNAs strongly distinguished CAD from controls. miR-1 significantly distinguished CAD from T2D with higher diagnostic ability than miR-133, whereas the miR-1/miR-133 combination improved the diagnostic value. Upregulation of circulating miR-1 and miR-133 associate with the risk of CAD in T2D patients and may serve as diagnostic biomarkers.
KeywordsCirculating miRNAs Type 2 diabetes Coronary artery disease Biomarkers
Low-density lipoprotein cholesterol
We would like to acknowledge the technical support of the Research Unit staff at Al-Jawhara Centre for Molecular Medicine, Genetics and Inherited Disorders in the College of Medicine and Medical Sciences, Arabian Gulf University.
The present study was supported by a research grant (No. 81) by the College of Medicine and Medical Sciences, Arabian Gulf University, Kingdom of Bahrain and a PhD Research Grant by Kingdom of Saudi Arabia.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical approval to conduct the current study was obtained from the Medical Research and Ethics Committee in the College of Medicine and Medical Sciences, Arabian Gulf University, Kingdom of Bahrain. The participants were given a complete description of the study, and provided written informed consents according to the guidelines of the College of Medicine and Medical Sciences, Arabian Gulf University, Kingdom of Bahrain.
- 2.IDF Diabetes Atlas 5th edition. (2011). https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/20-atlas-5th-edition.html.
- 8.Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., et al. (2007). Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ, 334(7588), 299.CrossRefGoogle Scholar
- 17.Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513–10518.CrossRefGoogle Scholar
- 21.Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H. A., Skrypnyk, C., Sabry, M. A., & Ramadan, A. R. (2016). Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Experimental and Therapeutic Medicine, 12(2), 815–822.CrossRefGoogle Scholar
- 39.Wong, L., Lee, K., Russell, I., & Chen, C. (2007). Endogenous controls for real time quantitation of miRNA using TaqManVR MicroRNA assays. New York: Macmillan Publishers Ltd..Google Scholar
- 43.Terentyev, D., Belevych, A. E., Terentyeva, R., Martin, M. M., Malana, G. E., Kuhn, D. E., et al. (2009). miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circulation Research, 104, 514–521.CrossRefGoogle Scholar
- 50.Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., Jr., & Fuster, V. (1999). Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American heart association and the American college of cardiology. Circulation, 100, 1481–1492.CrossRefGoogle Scholar